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Abstract
Hereditary non-polyposis colorectal cancer (HNPCC), also known as Lynch syndrome, is an autosomal
dominant inherited predisposition to a number of epithelial cancers, most notably colorectal and
endometrial cancer. Outside of the context of Lynch syndrome there is little evidence for an autosomal
dominant or recessive condition that predisposes to endometrial cancer. Recently, genetic variants in
MUTYH have been associated with a recessive form of colorectal cancer, known as MUTYH associated
polyposis or MAP. MUTYH is involved in base excision repair of DNA lesions and as such a breakdown in
the fidelity of this process would necessarily not be predicted to result in a specific disease. At present
there is little information about the role of MUTYH in other types of cancer and only one report indicating
a possible relationship with endometrial cancer.
Similar to a previous study, we investigated a series of endometrial cancer patients to determine if MUTYH
variants were over-represented compared to a series of healthy control subjects and to assess whether
or not endometrial cancer risk could be explained by an autosomal recessive model of inheritance.
Two MUTYH mutations, Y165C and G382D, and three common MUTYH polymorphisms, V22M, Q324H
and S501F, were genotyped in 213 endometrial cancer patients and 226 controls from Australia using real
time PCR. Differences in genotype frequencies were compared using Chi-squared analysis and by
calculating odds ratios and 95% confidence intervals.
Three endometrial cancer patients were identified with heterozygous MUTYH mutations (two G382D
and one Y165C). No bi-allelic mutation carriers were identified. Two of the three patients' clinical
characteristics were similar to those commonly identified in HNPCC and lend support to the notion that
MUTYH mutations increase the risk of developing HNPCC related diseases. There was no difference in
the five genotype frequencies of the endometrial cancer patients compared to the controls. The results of
our study suggest that MUTYH is unlikely to be involved in the genetic basis of endometrial cancer but a
possible association of MUTYH variants with HNPCC related diseases cannot be excluded.
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Background
MUTYH (MYH) is a DNA glycosylase which plays an
essential role in the base excision repair (BER) pathway to
prevent the accumulation of mutations that are a result of
oxidative DNA damage [1]. In 2002, two autosomal reces-
sive inherited mutations in MUTYH, Y165C and G382D,
were associated with adenomatous polyposis and colorec-
tal cancer [2], and several additional studies have con-
firmed that bi-allelic mutation carriers have an increased
risk of developing colorectal cancer [3-5]. These two
mutations are reported to account for approximately 86%
of all variations in the MUTYH gene that are identified in
Caucasians [6].
Some studies have suggested that mono-allelic changes in
MUTYH increase colorectal cancer risk however this
remains to be confirmed [3,4]. Furthermore, association
studies assessing mono-allelic changes in MUTYH in com-
bination with DNA mismatch repair genes, have revealed
a possible relationship, specifically between hMSH2 and
hMSH6, and an increased risk of developing colorectal
cancer although this remains to be definitively confirmed
[7,8]. Mutations in MMR genes are associated with hered-
itary non-polyposis colorectal cancer (HNPCC) which is
an autosomal dominant inherited predisposition to
colorectal cancer, endometrial cancer and a number of
other malignancies [9]. Results from previous studies
point towards a role of MUTYH mutations in HNPCC and
suggest that they may be involved in a larger spectrum of
disease involving extra-colonic cancers [7,8].
The role of MUTYH mutations in extra-colonic cancers
has previously been reviewed and there are indications
that this gene is associated with a broader spectrum of dis-
ease [6]. The report by Barnetson et al. (2005) focused on
determining whether or not variants in MUTYH were
related to endometrial cancer risk [6]. They identified one
patient that was a compound heterozygote for Y165C and
G382D. This patient had a sebaceous carcinoma which is
a feature of Muir-Torre syndrome and is associated with
MMR gene mutations. Five patients heterozygous for
either Y165C or G382D were also identified. These
MUTYH heterozygous mutation carriers did not harbour
other pathogenic mutations, only a number of intronic
variants. Since their conclusion that bi-allelic changes
may increase susceptibility to endometrial cancer is based
on one patient, these results need to be confirmed in a
larger number of endometrial cancer cases.
In addition to the common MUTYH mutations, Y165C
and G382D, three common polymorphisms in the Cauca-
sian population have been identified: V22M, Q324H and
S501F [2]. These polymorphisms have been suggested as
being associated with an increased risk of developing
colorectal cancer, however, it remains to be determined if
these changes are tissue specific with respect to disease
risk. Notwithstanding, these five MUTYH variants repre-
sent a significant proportion of the genetic variation
present in MUTYH and warrant further investigation.
To confirm if the two common MUTYH mutations,
Y165C and G382D and three common polymorphisms,
Q324H, V22M and S501F are associated with endome-
trial cancer, 191 endometrial cancer patients were geno-
typed for these 5 variants.
Materials and methods
Study population
This study initially consisted of 213 consecutively
recruited women with histologically confirmed endome-
trial cancer who presented for treatment at the Hunter
Centre for Gynaecological Cancer, John Hunter Hospital,
Newcastle, New South Wales, Australia between the years
1992 and 2005. Women that had additionally been diag-
nosed with breast cancer were excluded from this study.
The final analysis included 191 endometrial cancer
patients. Data on reproductive and environmental risk
factors including ethnicity, body mass index (BMI), diabe-
tes, high blood pressure (HBP), age of diagnosis of
endometrial cancer, age of menarche, age of menopause,
other personal cancer history, family cancer history (Fam-
ily history of cancer was defined as cancer in the index
patient plus one or more 1st or 2nd degree relatives diag-
nosed with cancer), parity, breastfeeding, oral contracep-
tive use, chemotherapy, radiotherapy, hormone
replacement therapy (HRT), smoking and alcohol use was
collected using self reported questionnaires. Information
regarding recurrence, stage, grade and histology of
endometrial cancer was collected from the medical
records. Two healthy anonymous control populations
were used in this study from the Hunter Area of Newcas-
tle. DNA samples were collected between the years of
1993 and 1997. For the Q324H, V22M and S501F poly-
morphisms, 226 patients were genotyped, and for the
Y165C and G382D variants, 120 patients were genotyped
and had a mean age of 51 years.
All participants provided informed written consent prior
to participation in this study. Ethics approval was
obtained from the Human Research Ethics Committee,
University of Newcastle and the Hunter Area Research
Ethics Committee, Hunter New England Health Service,
Newcastle, New South Wales, Australia.
DNA isolation
Genomic DNA was extracted from 10 ml EDTA blood as
previously described [10].Hereditary Cancer in Clinical Practice 2009, 7:3 http://www.hccpjournal.com/content/7/1/3
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Molecular analysis
Genotyping of the five MUTYH polymorphisms Y165C,
G382D, S501F, Q324H and V22M were performed on an
ABI PRISM® 7500 Real-Time PCR System (PE Applied Bio-
systems, Foster City, CA), using primers and probes from
Assay-by-Demand (Q324H and V22M) (assay ID: Q324H
– C___27504565_10 and V22M – C___25955644_10)
and Assay-by-Design (Y165C, G382D and S501F)
(Applied Biosystems). The primers and probes for Y165C,
G382D and S501F are listed in table 1. All assays were per-
formed under universal conditions previously described
[11]. Briefly, the assay functioned under universal condi-
tions with each reaction containing: 50 ng DNA, 0.125 μl
40× Assay Mix and 2.5 μl TaqMan® Universal PCR master
m i x  m a d e  u p  t o  5  μl with sterile water. The thermal
cycling conditions were 50°C for 2 min, 95°C for 10 min,
and 50 cycles of 92°C for 15 sec and 60°C for 1 min. Post
PCR, the plate was scanned to allow discrimination
between the different genotypes. The genotyping results
were confirmed by a second laboratory research assistant
and 5% of the samples were re-genotyped with 100% con-
cordance. Any sample where a genotype could not be
accurately assessed was re-genotyped. If it failed a second
time, it was discarded from the analysis. The overall call
rates were in the range from 96.0–100%.
Statistical analysis
To determine differences in genotype frequencies between
the cases and controls, chi-squared (χ2) statistics and odds
ratios and 95% CIs were calculated. T-tests were used to
determine differences in the age of diagnosis of endome-
trial cancer by genotype. The significance levels of all tests
were set at p < 0.05 and were two-sided. All statistical anal-
ysis was performed with Intercooled STATA 8.2 (Stata
Corp., College Station, TX, USA), SPSS Version 15 (SPSS
Inc. Chicago, IL, USA).
Results
The genotype frequencies were compared between the
cases and controls for the two MUTYH mutations and the
three MUTYH polymorphisms however no significant dif-
ferences were observed (see table 2). We included
endometrial cancer cases that were likely to be a result of
tamoxifen treatment as they had previously been diag-
nosed with breast cancer. These patients did not alter the
genotype frequency results for the three polymorphisms
nor did these patients have a mutation in Y165C or
G382D.
For the pathogenic MUTYH mutations, Y165C and
G382D, there were only 3 patients identified with hetero-
zygous changes, 2 for G382D and 1 for Y165C. No bi-
allelic changes were identified. Additionally, these
women did not harbour any of the three common poly-
morphisms, V22M, Q324H or S501F. The characteristics
of the MUTYH Y165C and G382D heterozygous mutation
carriers are in table 3. Two of these patients had family
histories of cancer that are possibly associated with a diag-
nosis of Lynch Syndrome as they both had first degree rel-
atives with colorectal cancer. The other patient did not
have any family history of disease.
T-tests were used to evaluate the influence of the five
MUTYH polymorphisms on the age of diagnosis of
endometrial cancer. No significant differences were
observed (data not shown).
Discussion
Currently, patients with multiple colorectal adenomas, no
APC gene mutation or HNPCC related colorectal cancer
and no MMR gene mutation are recommended to
undergo testing for germline mutations in MUTYH. It is
not known whether mutations or polymorphisms in
MUTYH are specific for colorectal cancer or if they encom-
pass a larger spectrum of disease, especially that which is
over-represented in Lynch Syndrome. Since the MMR
genes, hMSH2 and hMSH6 are associated with HNPCC
and evidence suggests that they directly interact with
MUTYH, it is possible that MUTYH mutations are related
to HNPCC extra-colonic cancers, specifically endometrial
cancer.
This study identified three endometrial cancer patients
with heterozygous Y165C or G382D changes in MUTYH.
No bi-allelic mutation carriers were identified in 191
endometrial cancer patients, however the monoallelic
Table 1: Real-Time PCR Assay-by-Design Primers and Probes for MUTYH Y165C, G382D and S501F
SNP Forward Reverse Wild Type Probe Mutant Probe
MUTYH S501 (C>T) CAGCCTTCCAAAAGGTT
CCCA
GCTGTGTGCATCAGTG
GAGAT
VIC-
CACGGAGAGGACAC
FAM-
CACGGAAAGGACAC
MUTYH Y165C (A>G) CCACAGGAAGGTGAATC
AACTCT
CCTTACCTTCCGAGCTC
CCT
VIC-
CTGGGCTACTATTCT
FAM-GGGCTGCTATTCT
MUTYH G382D (G>A) GACCCCTGCCTGGCT GACGGGAACTCCCACA
GT
VIC-
CCTCTCAGGTCTGCTG
FAM-
CCTCTCAGATCTGCTG
Note: The mutation/polymorphism is underlined in the probe sequences.
* The MUTYH S501F polymorphism is designed on the reverse strand.Hereditary Cancer in Clinical Practice 2009, 7:3 http://www.hccpjournal.com/content/7/1/3
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mutation carriers could possibly have other rare altera-
tions that were not investigated. Our results are similar to
a previous study which found one bi-allelic mutation car-
rier and five patients with heterozygous changes [6]. Two
of the three patients with heterozygous changes had a
family history of colorectal and endometrial cancer which
could possibly reflect their relationship with HNPCC.
We analysed three additional common polymorphisms in
MUTYH, Q324H, V22M and S501F, but did not find a sec-
ond variant in the women with heterozygous Y165C or
G382D mutations. It is highly unlikely that these women
harbour another as yet unidentified polymorphism since
the analysis of these five polymorphisms accounts for a
large majority of genetic variation in MUTYH in Cauca-
sians. Additionally, we compared the genotype frequen-
cies for all five MUTYH variants but did not find a
significant difference between the endometrial cancer
group and the controls which suggests that these variants
do not appear to increase the risk of developing endome-
trial cancer, although a larger population is required to
confirm this statement.
Table 2: The five MUTYH variants and their association with endometrial cancer risk
Polymorphisms Genotype Cases n (%) Controls n (%) X2 OR (95% CI) and p value
MUTYH Y165C (A>G) AA 190 (99.5) 120 (100) 1.00 (reference)
AG 1 90.5) 0 (0.0) P = 0.43 0.53 (0.02–13.1) p = 0.43
GG 0 (0.0) 9 (0.0)
MUTYH G382D (G>A) GG 189 (99.0) 118 (98.3) 1.00 (reference)
GA 2 (1.0) 2 (1.7) p = 0.6 41.6 (0.22–11.5) p = 0.63
AA 0 (0.0) 0 (0.0)
MUTYH V22M (G>A) GG 172 (90.1) 194 (85.8) 1.00 (reference)
GA 17 (8.9) 31 (13.7) 1.62 (0.86–3.02) p = 0.17
AA 2 (1.0) 1 (0.4) 0.44 (0.04–4.94) p = 0.92
MUTYH Q324H (G>C) GG 109 (57.1) 129 (59.2) 1.00 (reference)
GC 71 (37.2) 75 (34.4) p = 0.83 0.89 (0.59–1.35) p = 0.66
CC 11 (5.8) 14 (6.4) 1.08 (0.4&-2.47) p = 0.86
MUTYH S501F (C>T) CC 187 (97.9) 210 (96.8) 1.00 (reference)
CT 4 (2.1) 7 (3.2) p = 0.48 1.56 (0.45–5.41) p = 0.69
TT 0 (0.0) 0 (0.0)
Table 3: Characteristics of MUTYH Y165C and G382D heterozygous mutation carriers
Characteristics Y165C – patient 1 G382D – patient 2 G382D – patient 3
Year of Birth 1933 1935 1951
BMI (kg/m2) >30 25–30 25–30
Age of Diagnosis of Endometrial 
cancer (years)
71 70 52
Age of Menarche 15 16 15
Age of Menopause 55 45 52
No. of Children 0 3 2
Oral Contraceptive Never Use Never Never
Other Diseases High Blood Pressure Ovarian 
Cancer Colorectal Cancer
High Blood Pressure Diabetes Diabetes
Family History of Sister Cancer Colorectal cancer Mother & 
Maternal Aunt Breast Cancer
Father Colorectal Brother 
Leukaemia
None
Stage of Cancer Unknown 1B Mixed Mullerian Malignant Tumour
Grade of Cancer 1 1 3
Histology Adenocarcinoma Adenocarcinoma Mixed Mullerian Malignant Tumour
Recurrence None None None
Smoker Never Current Never
Alcohol Non-Drinker Non-Drinker Non-DrinkerPublish with BioMed Central    and   every 
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Our results suggest that the MUTYH mutations, Y165C
and G382D, only account, if at all, for a minority of
endometrial cancer cases. We can not rule out the possi-
bility that these mutations may act as modifiers of disease
penetrance since they both have been predicted to interact
functionally with hMSH2 and hMSH6. Furthermore, it is
not clear whether there are tissue specific differences in
disease expression that may be related to environmental
influences that are specific for each anatomical site.
Recently, a study of over 600 breast cancer cases also
revealed similar results to our own in that no bi-allelic
mutations were identified and there was no change in the
risk of disease in mono-allelic carriers. Together, the com-
bined results suggest that MUTYH is not associated with
an increased risk of breast cancer [12] or endometrial can-
cer.
In conclusion, our results in combination with Barnetson
et al. (2005) [6] reveal that variation in MUTYH is very
limited in endometrial cancer and does not appear to alter
the susceptibility to sporadic endometrial cancer however
MUTYH variants possibly have some role in HNPCC
related disease.
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